Following our initial results with CCP, in this study, we focused on patients with severe type-2 high asthma, the target population for anti-IL5/anti-IL5R monoclonal antibodies, to explore (1) the relationship of these novel inhomogeneity indices with other parameters and characteristics in this patient cohort, such as inflammatory biomarkers and symptoms and (2) whether the novel CCP inhomogeneity indices change with therapy. This evidence concerns the gene IL5RA and asthma.